HFA-152a

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 1

Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants

CompletedNCT06506266

GlaxoSmithKlineAsthma

Start: 2024-07-29End: 2024-10-24Updated: 2026-04-14

Phase 3

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

Not yet recruitingNCT07645248

GlaxoSmithKlineAsthma

Start: 2026-09-15End: 2027-02-25Target: 110Updated: 2026-06-12

Related Papers

Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.

2026-07-21